K. S. Ataman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
K. S. Ataman has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Sergey Nikolaevich Avdeev
Sechenov First Moscow State Medical University, Moscow, Russia
11 shared publications - Zamira Magomedovna Merzhoeva
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
9 shared publications - Galina Vasilyevna Nekludova
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Federal State Budgetary Institution “Pulmonology Scientific Research Institute” under Federal Medical and Biological Agency of Russian Federation
6 shared publications - Natalia A. Tsareva
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
5 shared publications - Viliya V. Gaynitdinova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
5 shared publications - Anna A. Proshkina
Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications
Latest Publications
- 14 October 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (3)
Remote monitoring of patients with chronic obstructive pulmonary disease: results of a multicentre pilot study
Objective. To evaluate the results of a multicentre randomized pilot study of remote monitoring (RM) in patients with chronic obstructive pulmonary disease (COPD). Material and methods. A multicentre, randomized, open-label study. Patients with a verified diagnosis of COPD were randomized 1:1 to either the RM group or the standard follow-up care group (control): a total of 67 patients were enrolled (RM — 33, control — 34). The participation duration was 14 weeks. This paper presents the results of the analysis of patients enrolled at the time of publication preparation (Sechenov University centre). The analysis was performed in the mITT population (N=55: RM 29 patients, control 26). The primary endpoint included: relative change in FEV1, absolute change in the frequency of short-acting bronchodilator (SABD) use, and estimated annual exacerbation rate of COPD at week 12. Results. The relative change in FEV1 at week 12 was +2.65% in the RM group and −6.55% in the control group; the absolute FEV1 value was 70.15% vs 59.99% of predicted (p=0.164). The RM group showed a reduction in the estimated annual COPD exacerbation rate (1.38 vs 2.12; p=0.016); however, this result requires cautious interpretation given the correction for multiple comparisons; the categorical distribution of exacerbations differed significantly (p=0.008). The frequency of SABD use at week 12 was 1.19 vs 1.69 doses/day (p=0.098). The CAT score consistently decreased in the RM group: −2.04 (p=0.021), −2.91 (p=0.020), and −3.33 (p=0.012) at weeks 2, 6, and 12, respectively. The proportion of patients with severe dyspnoea on the Borg scale (≥5 points) was significantly lower in the RM group at week 12 (p=0.027). Mean adherence to monitoring exceeded 80% across all parameters. No unplanned healthcare visits were recorded in the RM group vs 3 cases (11.54%) in the control group (p=0.099). Conclusion. The RM group demonstrated a reduction in the estimated annual COPD exacerbation rate, as well as sustained positive trends in functional and symptomatic outcomes. High patient adherence confirms the feasibility of the RM programme in real-world practice. The findings highlight the need to continue the study in order to obtain more robust data.
- 14 October 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (3)
Remote monitoring of patients with chronic obstructive pulmonary disease: results of a multicentre pilot study
Objective. To evaluate the results of a multicentre randomized pilot study of remote monitoring (RM) in patients with chronic obstructive pulmonary disease (COPD). Material and methods. A multicentre, randomized, open-label study. Patients with a verified diagnosis of COPD were randomized 1:1 to either the RM group or the standard follow-up care group (control): a total of 67 patients were enrolled (RM — 33, control — 34). The participation duration was 14 weeks. This paper presents the results of the analysis of patients enrolled at the time of publication preparation (Sechenov University centre). The analysis was performed in the mITT population (N=55: RM 29 patients, control 26). The primary endpoint included: relative change in FEV1, absolute change in the frequency of short-acting bronchodilator (SABD) use, and estimated annual exacerbation rate of COPD at week 12. Results. The relative change in FEV1 at week 12 was +2.65% in the RM group and −6.55% in the control group; the absolute FEV1 value was 70.15% vs 59.99% of predicted (p=0.164). The RM group showed a reduction in the estimated annual COPD exacerbation rate (1.38 vs 2.12; p=0.016); however, this result requires cautious interpretation given the correction for multiple comparisons; the categorical distribution of exacerbations differed significantly (p=0.008). The frequency of SABD use at week 12 was 1.19 vs 1.69 doses/day (p=0.098). The CAT score consistently decreased in the RM group: −2.04 (p=0.021), −2.91 (p=0.020), and −3.33 (p=0.012) at weeks 2, 6, and 12, respectively. The proportion of patients with severe dyspnoea on the Borg scale (≥5 points) was significantly lower in the RM group at week 12 (p=0.027). Mean adherence to monitoring exceeded 80% across all parameters. No unplanned healthcare visits were recorded in the RM group vs 3 cases (11.54%) in the control group (p=0.099). Conclusion. The RM group demonstrated a reduction in the estimated annual COPD exacerbation rate, as well as sustained positive trends in functional and symptomatic outcomes. High patient adherence confirms the feasibility of the RM programme in real-world practice. The findings highlight the need to continue the study in order to obtain more robust data.
- Open Access
- 14 July 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 113-122
Clinical and functional predictors of pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Introduction . Idiopathic pulmonary fibrosis (IPF) is frequently complicated by pulmonary hypertension (PH), the prevalence of which reaches 50–80% among patients awaiting lung transplantation. At the same time, the accuracy of transthoracic echocardiography as the main screening method for PH in patients with IPF is limited, which determines the need for simple non-invasive functional tests to select patients for further in-depth evaluation. Aim . To determine the clinical and functional predictors of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Materials and methods. The study included 121 patients with IPF. Based on echocardiography findings, the patients were divided into two groups: without PH (PASP Results . The groups did not differ significantly in age, sex, BMI, or smoking status. In patients with PH, cardiovascular events were significantly more frequent (59 vs. 26%, p < 0.001), as was chronic heart failure (55 vs. 23%, p = 0.001). The Charlson Comorbidity Index (p = 0.027) and dyspnea severity according to the mMRC scale (p = 0.022) were higher in the PH group. Absolute DLCO was lower in the PH group (8.5 vs. 10.1 mL/min/mmHg, p = 0.041). The level of desaturation during the 6MWT was higher, and post-6MWT SpO₂ was lower in the PH group (p = 0.002 and p = 0.001, respectively). ROC analysis identified the following cut-off values: post-6MWT SpO₂ 9%, post-6MWT SpO₂ <84%) may be utilized for screening purposes.
- 14 July 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 113-122
Open AccessClinical and functional predictors of pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Introduction . Idiopathic pulmonary fibrosis (IPF) is frequently complicated by pulmonary hypertension (PH), the prevalence of which reaches 50–80% among patients awaiting lung transplantation. At the same time, the accuracy of transthoracic echocardiography as the main screening method for PH in patients with IPF is limited, which determines the need for simple non-invasive functional tests to select patients for further in-depth evaluation. Aim . To determine the clinical and functional predictors of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Materials and methods. The study included 121 patients with IPF. Based on echocardiography findings, the patients were divided into two groups: without PH (PASP Results . The groups did not differ significantly in age, sex, BMI, or smoking status. In patients with PH, cardiovascular events were significantly more frequent (59 vs. 26%, p < 0.001), as was chronic heart failure (55 vs. 23%, p = 0.001). The Charlson Comorbidity Index (p = 0.027) and dyspnea severity according to the mMRC scale (p = 0.022) were higher in the PH group. Absolute DLCO was lower in the PH group (8.5 vs. 10.1 mL/min/mmHg, p = 0.041). The level of desaturation during the 6MWT was higher, and post-6MWT SpO₂ was lower in the PH group (p = 0.002 and p = 0.001, respectively). ROC analysis identified the following cut-off values: post-6MWT SpO₂ 9%, post-6MWT SpO₂ <84%) may be utilized for screening purposes.
- Open Access
- 14 July 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 132-141
Echocardiographic determinants of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: Association with clinical and functional status
Introduction . Pulmonary hypertension (PH) frequently complicates the course of idiopathic pulmonary fibrosis (IPF) and worsens its prognosis; however, echocardiographic signs of right heart chamber remodeling and clinical and functional factors associated with systolic pulmonary artery pressure (PASP) level in IPF remain insufficiently studied. Aim . To characterize echocardiographic changes in the right heart chambers in patients with idiopathic pulmonary fibrosis depending on the presence of pulmonary hypertension and to identify clinical and functional factors associated with the value of systolic pulmonary artery pressure. Materials and methods. The study included 121 patients with IPF. Based on echocardiography, patients were divided into groups without PH (PASP < 35 mmHg, n = 35) and with PH (PASP ≥ 35 mmHg, n = 86). Right atrial area (RA area), mean right ventricular diameter (RV diameter), TAPSE, TAPSE/PASP ratio, and left ventricular ejection fraction (LVEF) were assessed. Spearman correlation analysis, univariate and multivariate linear regression analysis with PASP as a continuous variable were performed. Results. The PH group showed larger RA area (17.0 vs 13.5 cm², p < 0.001), larger RV diameter (4.00 vs 3.75 cm, p < 0.001), and a lower TAPSE/PASP ratio (0.438 vs 0.697, p < 0.001) with no difference in absolute TAPSE (p = 0.941). LVEF was slightly lower in the PH group (61% vs 62%, p = 0.016) but remained within normal limits. PASP correlated positively with RA area (r = 0.491, p = 0.019) and desaturation level during 6MWT (r = 0.355, p < 0.001), and negatively with post-exercise SpO₂ (r = -0.336, p = 0.001). DLCO correlated positively with post-exercise SpO₂ (r = 0.347, p = 0.001) and negatively with mMRC (r = -0.338, p = 0.001) and desaturation (r = -0.270, p = 0.014). Univariate linear regression showed associations of PASP with cardiovascular events (β = 10.8), CHF (β = 10.9), desaturation (β = 1.02 per 1%), post-exercise SpO₂ (β = -0.603), mMRC (β = 4.52), LTOT duration (β = 3.74 per year), and LVEF (β = -0.562). In multivariate linear regression, independent determinants of PASP were the Charlson comorbidity index (β = 2.205 per 1 point; p = 0.006), desaturation level (β = 1.153 per 1%; p < 0.001), and LTOT duration (β = 4.281 per year; p = 0.020). Conclusion . In patients with IPF, pulmonary hypertension is associated with right heart remodeling (enlarged RA area, RV diameter) and reduced right ventricular-pulmonary arterial coupling (decreased TAPSE/PASP ratio) despite preserved TAPSE. Independent determinants of PASP value are comorbidity burden (Charlson index), desaturation during exercise, and long-term oxygen therapy duration.
- 14 July 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 132-141
Open AccessEchocardiographic determinants of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: Association with clinical and functional status
Introduction . Pulmonary hypertension (PH) frequently complicates the course of idiopathic pulmonary fibrosis (IPF) and worsens its prognosis; however, echocardiographic signs of right heart chamber remodeling and clinical and functional factors associated with systolic pulmonary artery pressure (PASP) level in IPF remain insufficiently studied. Aim . To characterize echocardiographic changes in the right heart chambers in patients with idiopathic pulmonary fibrosis depending on the presence of pulmonary hypertension and to identify clinical and functional factors associated with the value of systolic pulmonary artery pressure. Materials and methods. The study included 121 patients with IPF. Based on echocardiography, patients were divided into groups without PH (PASP < 35 mmHg, n = 35) and with PH (PASP ≥ 35 mmHg, n = 86). Right atrial area (RA area), mean right ventricular diameter (RV diameter), TAPSE, TAPSE/PASP ratio, and left ventricular ejection fraction (LVEF) were assessed. Spearman correlation analysis, univariate and multivariate linear regression analysis with PASP as a continuous variable were performed. Results. The PH group showed larger RA area (17.0 vs 13.5 cm², p < 0.001), larger RV diameter (4.00 vs 3.75 cm, p < 0.001), and a lower TAPSE/PASP ratio (0.438 vs 0.697, p < 0.001) with no difference in absolute TAPSE (p = 0.941). LVEF was slightly lower in the PH group (61% vs 62%, p = 0.016) but remained within normal limits. PASP correlated positively with RA area (r = 0.491, p = 0.019) and desaturation level during 6MWT (r = 0.355, p < 0.001), and negatively with post-exercise SpO₂ (r = -0.336, p = 0.001). DLCO correlated positively with post-exercise SpO₂ (r = 0.347, p = 0.001) and negatively with mMRC (r = -0.338, p = 0.001) and desaturation (r = -0.270, p = 0.014). Univariate linear regression showed associations of PASP with cardiovascular events (β = 10.8), CHF (β = 10.9), desaturation (β = 1.02 per 1%), post-exercise SpO₂ (β = -0.603), mMRC (β = 4.52), LTOT duration (β = 3.74 per year), and LVEF (β = -0.562). In multivariate linear regression, independent determinants of PASP were the Charlson comorbidity index (β = 2.205 per 1 point; p = 0.006), desaturation level (β = 1.153 per 1%; p < 0.001), and LTOT duration (β = 4.281 per year; p = 0.020). Conclusion . In patients with IPF, pulmonary hypertension is associated with right heart remodeling (enlarged RA area, RV diameter) and reduced right ventricular-pulmonary arterial coupling (decreased TAPSE/PASP ratio) despite preserved TAPSE. Independent determinants of PASP value are comorbidity burden (Charlson index), desaturation during exercise, and long-term oxygen therapy duration.
- 2 July 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (2)
Electronic lung auscultations in pulmonology: from clinical skill to digital diagnostics
Lung auscultation remains a fundamental method for the clinical diagnosis of respiratory diseases; however, its effectiveness is limited by subjective interpretation and interobserver variability (kappa coefficient (Κ) 0.4—0.6). Advances in digital technologies have led to the emergence of electronic auscultation as a tool for the objectification and standardization of auscultatory data. Objective. To systematize data on modern electronic stethoscopes, open-access respiratory sound databases, artificial intelligence (AI) algorithms, and telemedicine capabilities, with an assessment of their clinical applicability. Material and methods. A literature review was conducted using publications retrieved from PubMed/MEDLINE, Embase, IEEE Xplore (Institute of Electrical and Electronics Engineers), and eLIBRARY.RU databases for the period 2000—2025. Results. Modern devices perceive an extended frequency range (up to 2000 Hz), provide recording, visualization, and transmission of data to medical information systems. Deep learning algorithms — convolutional neural networks, long short-term memory networks, and vision transformers — demonstrate classification accuracy of respiratory sounds ranging from 79% to 99% on public datasets. Key limitations identified include the lack of unified data storage standards, inter-device variability in amplitude—frequency characteristics, insufficient clinical validation, and limited integration with international standards for medical data exchange and the Unified State Health Information System. Conclusion. Electronic auscultation is a key component in transition to digital respiratory medicine. Its full-scale implementation requires the development of regulatory standards, creation of multicenter national respiratory sound databases, and clinical validation of AI algorithms.
- 2 July 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (2)
Electronic lung auscultations in pulmonology: from clinical skill to digital diagnostics
Lung auscultation remains a fundamental method for the clinical diagnosis of respiratory diseases; however, its effectiveness is limited by subjective interpretation and interobserver variability (kappa coefficient (Κ) 0.4—0.6). Advances in digital technologies have led to the emergence of electronic auscultation as a tool for the objectification and standardization of auscultatory data. Objective. To systematize data on modern electronic stethoscopes, open-access respiratory sound databases, artificial intelligence (AI) algorithms, and telemedicine capabilities, with an assessment of their clinical applicability. Material and methods. A literature review was conducted using publications retrieved from PubMed/MEDLINE, Embase, IEEE Xplore (Institute of Electrical and Electronics Engineers), and eLIBRARY.RU databases for the period 2000—2025. Results. Modern devices perceive an extended frequency range (up to 2000 Hz), provide recording, visualization, and transmission of data to medical information systems. Deep learning algorithms — convolutional neural networks, long short-term memory networks, and vision transformers — demonstrate classification accuracy of respiratory sounds ranging from 79% to 99% on public datasets. Key limitations identified include the lack of unified data storage standards, inter-device variability in amplitude—frequency characteristics, insufficient clinical validation, and limited integration with international standards for medical data exchange and the Unified State Health Information System. Conclusion. Electronic auscultation is a key component in transition to digital respiratory medicine. Its full-scale implementation requires the development of regulatory standards, creation of multicenter national respiratory sound databases, and clinical validation of AI algorithms.
- 22 June 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (3)
Predictors of severe pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease with a poor prognosis. The median survival after diagnosis does not exceed 2 – 3 years. One of the most significant complications of IPF is pulmonary hypertension (PH), the incidence of which is 20 – 84% and increases with the disease advancement. The aim of the study was to comparatively analyze the clinical, functional and echocardiographic characteristics of patients with IPF depending on the degree of PH and to evaluate the diagnostic value of non-invasive parameters for detecting severe PH. Methods . The observational study included patients ( n = 121; median age – 69 years) with verified IPF. Depending on the pulmonary artery systolic pressure (PASP), the patients were divided into 3 groups. Group 1 ( n = 35) included patients without PH (PASP < 35 mmHg). Group 2 ( n = 59) included individuals with moderate PH (PASP 35 – 59 mmHg). Group 3 ( n = 27) included patients with severe PH (PASP ≥ 60 mmHg). Clinical data, Charlson Comorbidity Index, 6-minute walk test (6-MWT), spirometry, diffusing capacity of the lungs for carbon monoxide (DLCO), high-resolution computed tomography (HRCT), and transthoracic echocardiography were assessed. Diagnostic accuracy was determined using ROC analysis, and the association with severe PH was determined using univariate and reduced multivariate logistic regression. Results . As PASP increased, the incidence of cardiovascular events (26% vs 53% vs 74%, respectively; p < 0.001) and chronic heart failure (23% vs 47% vs 70%, respectively; p < 0.001) also grew, dyspnea progressed (modified Medical Research Council dyspnea scale – mMRC – 4 points: 8.6% vs 25% vs 41%, respectively; p = 0.049), desaturation rose during 6-MWT (7% vs 9% vs 12%, respectively; p = 0.002), and the right heart chambers dilated (the tricuspid annular systolic excursion (TAPSE) / PASP ratio was 0.697 vs 0.477 vs 0.317, respectively; p < 0.001). Spirometry parameters and DLCO did not differ between the groups. The degree of desaturation during the 6-MWT had the highest diagnostic value for detecting severe PH (AUC = 0.721: p = 0.005; sensitivity – 80%, specificity – 64% at the threshold > 9%). In the reduced multivariate model, desaturation remained the only independent predictor of severe PH (odds ratio – 1.237; 95% confidence interval – 1.086 – 1.437; p = 0.003). Conclusion . Desaturation > 9% during the 6-MWT serves as a reliable non-invasive criterion for selecting patients with IPF for in-depth examination to detect severe
- 22 June 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (3)
Predictors of severe pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease with a poor prognosis. The median survival after diagnosis does not exceed 2 – 3 years. One of the most significant complications of IPF is pulmonary hypertension (PH), the incidence of which is 20 – 84% and increases with the disease advancement. The aim of the study was to comparatively analyze the clinical, functional and echocardiographic characteristics of patients with IPF depending on the degree of PH and to evaluate the diagnostic value of non-invasive parameters for detecting severe PH. Methods . The observational study included patients ( n = 121; median age – 69 years) with verified IPF. Depending on the pulmonary artery systolic pressure (PASP), the patients were divided into 3 groups. Group 1 ( n = 35) included patients without PH (PASP < 35 mmHg). Group 2 ( n = 59) included individuals with moderate PH (PASP 35 – 59 mmHg). Group 3 ( n = 27) included patients with severe PH (PASP ≥ 60 mmHg). Clinical data, Charlson Comorbidity Index, 6-minute walk test (6-MWT), spirometry, diffusing capacity of the lungs for carbon monoxide (DLCO), high-resolution computed tomography (HRCT), and transthoracic echocardiography were assessed. Diagnostic accuracy was determined using ROC analysis, and the association with severe PH was determined using univariate and reduced multivariate logistic regression. Results . As PASP increased, the incidence of cardiovascular events (26% vs 53% vs 74%, respectively; p < 0.001) and chronic heart failure (23% vs 47% vs 70%, respectively; p < 0.001) also grew, dyspnea progressed (modified Medical Research Council dyspnea scale – mMRC – 4 points: 8.6% vs 25% vs 41%, respectively; p = 0.049), desaturation rose during 6-MWT (7% vs 9% vs 12%, respectively; p = 0.002), and the right heart chambers dilated (the tricuspid annular systolic excursion (TAPSE) / PASP ratio was 0.697 vs 0.477 vs 0.317, respectively; p < 0.001). Spirometry parameters and DLCO did not differ between the groups. The degree of desaturation during the 6-MWT had the highest diagnostic value for detecting severe PH (AUC = 0.721: p = 0.005; sensitivity – 80%, specificity – 64% at the threshold > 9%). In the reduced multivariate model, desaturation remained the only independent predictor of severe PH (odds ratio – 1.237; 95% confidence interval – 1.086 – 1.437; p = 0.003). Conclusion . Desaturation > 9% during the 6-MWT serves as a reliable non-invasive criterion for selecting patients with IPF for in-depth examination to detect severe
- Open Access
- 9 October 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (5) , 646-655
Causes of hospitalization and their impact on the course of fibrosing interstitial lung diseases
Interstitial lung disease (ILD) is a diverse and heterogenous group of chronic lung diseases affecting lung parenchyma and characterized by inflammation followed by pulmonary fibrosis that can progress and lead to hospitalization. The impact of hospitalizations on the clinical course of ILD is not fully understood. The aim was to analyze the causes of hospitalization related to the underlying disease and their relationship with the clinical and functional features of the disease course in patients with fibrosing ILD (f-ILD). Methods. This study was an open comparative non interventional study. We analyzed findings from two groups of patients with f-ILD, who had or did not have hospitalizations due to respiratory reasons during the previous 12 months. Additionally, we analyzed demographic and clinical data, severity of ILD according to Gender, Age, Physiology (GAP) scale, lung function and echocardiographic parameters, physical tolerance in 6-minute walk test (6MWT), and pharmacological therapy. Results. Ninety-five patients with f-ILD were involved in the study. Of them, 37 patients had one to four previous hospitalizations due to respiratory reasons during the previous 12 months, and 58 patients did not have any hospitalizations during this period. Most frequent reasons for hospitalization were progressing or exacerbation of f-ILD, less frequent reasons were community-acquired pneumonia and other respiratory infections, and pulmonary embolism. One third of the patients (n = 29) were hospitalized for elective procedures to verify the diagnosis. Patients with previous hospitalizations had more severe course of f-ILD according to GAP scale, lower parameters of lung function, oxygenation, and physical tolerance and more often were treated with pharmacological agents and supplemental oxygen. Conclusion. Most common reasons for hospitalization of f-ILD patients were progressing or exacerbation of f-ILD and the need in elective procedures to verify the diagnosis. Patients hospitalized for respiratory reasons during the previous 12 months had more severe clinical course of the disease with lower lung function and physical tolerance and more often required pharmacological therapy and supplemental oxygen as compared to the patients who had no hospitalizations in this time interval. Further studies are needed to investigate the prognostic value of hospitalizations in f-ILD.
- 9 October 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (5) , 646-655
Open AccessCauses of hospitalization and their impact on the course of fibrosing interstitial lung diseases
Interstitial lung disease (ILD) is a diverse and heterogenous group of chronic lung diseases affecting lung parenchyma and characterized by inflammation followed by pulmonary fibrosis that can progress and lead to hospitalization. The impact of hospitalizations on the clinical course of ILD is not fully understood. The aim was to analyze the causes of hospitalization related to the underlying disease and their relationship with the clinical and functional features of the disease course in patients with fibrosing ILD (f-ILD). Methods. This study was an open comparative non interventional study. We analyzed findings from two groups of patients with f-ILD, who had or did not have hospitalizations due to respiratory reasons during the previous 12 months. Additionally, we analyzed demographic and clinical data, severity of ILD according to Gender, Age, Physiology (GAP) scale, lung function and echocardiographic parameters, physical tolerance in 6-minute walk test (6MWT), and pharmacological therapy. Results. Ninety-five patients with f-ILD were involved in the study. Of them, 37 patients had one to four previous hospitalizations due to respiratory reasons during the previous 12 months, and 58 patients did not have any hospitalizations during this period. Most frequent reasons for hospitalization were progressing or exacerbation of f-ILD, less frequent reasons were community-acquired pneumonia and other respiratory infections, and pulmonary embolism. One third of the patients (n = 29) were hospitalized for elective procedures to verify the diagnosis. Patients with previous hospitalizations had more severe course of f-ILD according to GAP scale, lower parameters of lung function, oxygenation, and physical tolerance and more often were treated with pharmacological agents and supplemental oxygen. Conclusion. Most common reasons for hospitalization of f-ILD patients were progressing or exacerbation of f-ILD and the need in elective procedures to verify the diagnosis. Patients hospitalized for respiratory reasons during the previous 12 months had more severe clinical course of the disease with lower lung function and physical tolerance and more often required pharmacological therapy and supplemental oxygen as compared to the patients who had no hospitalizations in this time interval. Further studies are needed to investigate the prognostic value of hospitalizations in f-ILD.
- 6 June 2025
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 1 (2)
The case of a patient with Mounier-Kun syndrome
Mounier-Kuhn syndrome (MKS) is a rare disease characterized by significant enlargement of tracheobronchial tree, recurrent cough and lower respiratory tract infections. Condition is typically diagnosed through imaging techniques such as computed tomography (CT) scans of the chest and bronchoscopy as well. There are asymptomatic or symptomatic cases in the disease while symptoms can be varied from minimal with preserved lung function to severe, including respiratory failure with recurrent pneumonia and bronchiectasis. Therapy is mainly symptomatic and aimed to manage symptoms. Surgery rarely has a place in the treatment of MKS. Although in the world literature reports of surgical interventions in some patients with MKS surgery have been presented, this type of treatment has not been widely adopted. Due to the lack of specific features in the clinical presentation of the condition, it should be taken into consideration in patients with recurrent episodes of pneumonia and frequent exacerbations of chronic bronchitis. This particular case is presented the patient with non-specific symptoms in the form of a non-productive cough and recurrent episodes of suffocation attacks. To evaluate the patient’s condition, CT of the chest and bronchoscopy are performed. These tests revealed tracheobronchomegaly and tracheal diverticula, which are both associated with the condition.
- 6 June 2025
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 1 (2)
The case of a patient with Mounier-Kun syndrome
Mounier-Kuhn syndrome (MKS) is a rare disease characterized by significant enlargement of tracheobronchial tree, recurrent cough and lower respiratory tract infections. Condition is typically diagnosed through imaging techniques such as computed tomography (CT) scans of the chest and bronchoscopy as well. There are asymptomatic or symptomatic cases in the disease while symptoms can be varied from minimal with preserved lung function to severe, including respiratory failure with recurrent pneumonia and bronchiectasis. Therapy is mainly symptomatic and aimed to manage symptoms. Surgery rarely has a place in the treatment of MKS. Although in the world literature reports of surgical interventions in some patients with MKS surgery have been presented, this type of treatment has not been widely adopted. Due to the lack of specific features in the clinical presentation of the condition, it should be taken into consideration in patients with recurrent episodes of pneumonia and frequent exacerbations of chronic bronchitis. This particular case is presented the patient with non-specific symptoms in the form of a non-productive cough and recurrent episodes of suffocation attacks. To evaluate the patient’s condition, CT of the chest and bronchoscopy are performed. These tests revealed tracheobronchomegaly and tracheal diverticula, which are both associated with the condition.
- 20 March 2025
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 1 (1)
Relationship of eosinophil level with severe COVID-19 outcomes in asthma of the elderly
There is a significant decrease in the eosinophil level of patients’ peripheral blood in COVID-19, and in most of them — at an early stage, regardless of the disease’s severity. It is believed that patients with bronchial asthma have a lower risk of adverse outcomes of COVID-19, and eosinophilia, both in patients with and without asthma, is associated with a reduced risk of mortality. Objective. To study the relationship of eosinophil level with the outcomes of severe COVID-19 in bronchial asthma of the elderly. Material and methods. The study included elderly patients (>60 years old (according to WHO classification, 2020), n=76) with documentally confirmed history of bronchial asthma (according to GINA criteria, 2020), hospitalized for severe COVID-19. Presence of COVID-19 was confirmed by laboratory tests (polymerase chain reaction) and/or clinically and radiologically. The patients were monitored at the hospital stage and within 1 month after discharge from the hospital. Calculation of odds ratio and 95% confidence intervals (95% CI) was done using single-factor and multi-factor logistic regression (IBM SPSS Statistics v. 22 application software package). Results. Analysis of eosinophil level depending on the disease’s outcome (survived/died) has shown that the median of eosinophil level in the group of survived patients was 30 [10; 100] (95% CI 13—60) cells/µL, and in the group of deceased — 16.5 [9; 39] (95% CI 11—29) cells/µL, the differences were statistically significant (p=0.04). The level of eosinophils above 100 cells/µL is associated with a favorable outcome of the disease, and the chance of survival at such eosinophil level is 13.5 (95% CI 1.6—242) times higher than at the level of eosinophils 100 cells/µg) was associated with lower glucose level (<7 mmol/L), lactate dehydrogenase (LDH) (<450 U/L) and respiratory rate (<23 per minute), thus the relationship between the chance of survival and eosinophil level remained statistically significant — OR 32.1 (95% CI 1.1—141) (p=0.04). Despite the existing relationship between the level of eosinophils and mortality, the relationship between the absolute number of eosinophils and the duration of hospitalization was not revealed. Conclusion. Elevated level of eosinophils in bronchial asthma of the elderly and severe COVID-19 is associated with a favorable outcome of the disease.
- 20 March 2025
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 1 (1)
Relationship of eosinophil level with severe COVID-19 outcomes in asthma of the elderly
There is a significant decrease in the eosinophil level of patients’ peripheral blood in COVID-19, and in most of them — at an early stage, regardless of the disease’s severity. It is believed that patients with bronchial asthma have a lower risk of adverse outcomes of COVID-19, and eosinophilia, both in patients with and without asthma, is associated with a reduced risk of mortality. Objective. To study the relationship of eosinophil level with the outcomes of severe COVID-19 in bronchial asthma of the elderly. Material and methods. The study included elderly patients (>60 years old (according to WHO classification, 2020), n=76) with documentally confirmed history of bronchial asthma (according to GINA criteria, 2020), hospitalized for severe COVID-19. Presence of COVID-19 was confirmed by laboratory tests (polymerase chain reaction) and/or clinically and radiologically. The patients were monitored at the hospital stage and within 1 month after discharge from the hospital. Calculation of odds ratio and 95% confidence intervals (95% CI) was done using single-factor and multi-factor logistic regression (IBM SPSS Statistics v. 22 application software package). Results. Analysis of eosinophil level depending on the disease’s outcome (survived/died) has shown that the median of eosinophil level in the group of survived patients was 30 [10; 100] (95% CI 13—60) cells/µL, and in the group of deceased — 16.5 [9; 39] (95% CI 11—29) cells/µL, the differences were statistically significant (p=0.04). The level of eosinophils above 100 cells/µL is associated with a favorable outcome of the disease, and the chance of survival at such eosinophil level is 13.5 (95% CI 1.6—242) times higher than at the level of eosinophils 100 cells/µg) was associated with lower glucose level (<7 mmol/L), lactate dehydrogenase (LDH) (<450 U/L) and respiratory rate (<23 per minute), thus the relationship between the chance of survival and eosinophil level remained statistically significant — OR 32.1 (95% CI 1.1—141) (p=0.04). Despite the existing relationship between the level of eosinophils and mortality, the relationship between the absolute number of eosinophils and the duration of hospitalization was not revealed. Conclusion. Elevated level of eosinophils in bronchial asthma of the elderly and severe COVID-19 is associated with a favorable outcome of the disease.
- Open Access
- 27 May 2024
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 34 (3) , 417-426
Efficacy and safety of high doses of inhaled nitric oxide in patients with community-acquired pneumonia: a pilot study
For the first time, the effectiveness and safety of high doses of inhaled nitric oxide (iNO) in patients with community-acquired pneumonia (CAP) has been demonstrated.The aim of the study was to examine the effectiveness and safety of adding iNO to standard treatment for patients with CAP.Methods. A pilot, single-center, prospective, randomized, open-label clinical trial was conducted, which included patients (n = 120) hospitalized with CAP. Randomization was carried out using the blind envelope method. Patients in the main group (n = 60) received iNO through nasal cannulas using the Tianox iNO therapy device (AIT-NO-Ol according to TU 32.50. 21-001-07623615-2017) in addition to the therapy according to the standard of care at the study center. Inhalations were carried out with high doses of NO, namely 200 ppm for 15 minutes 3 times a day, regardless of food intake. Patients in the control group (n = 60) received only the therapy recommended by the standard of care at the study center. Clinical and laboratory parameters were assessed and safety of the therapy was monitored during the study.Results. No significant differences were identified between the main group and the control group in demographic, clinical, laboratory and instrumental data at baseline. Patients receiving iNO as an adjunct to standard therapy had a more significant improvement in clinical symptoms starting from the 3rd day and better oxygenation parameters on the 7th day of therapy. There was a more significant decrease in the level of C-reactive protein on the 5th and 7th days of therapy and a more significant decrease in the level of leukocytes on the 5th day in the main group. The duration of hospitalization in the main group was significantly shorter than that in the control group. NO inhalation was not associated with any side effects and was well tolerated.Conclusion. The use of high doses of NO has a positive effect on the clinical status, markers of inflammation, reduces the length of hospitalization, and demonstrates good tolerability and safety in patients with CAP.
- 27 May 2024
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 34 (3) , 417-426
Open AccessEfficacy and safety of high doses of inhaled nitric oxide in patients with community-acquired pneumonia: a pilot study
For the first time, the effectiveness and safety of high doses of inhaled nitric oxide (iNO) in patients with community-acquired pneumonia (CAP) has been demonstrated.The aim of the study was to examine the effectiveness and safety of adding iNO to standard treatment for patients with CAP.Methods. A pilot, single-center, prospective, randomized, open-label clinical trial was conducted, which included patients (n = 120) hospitalized with CAP. Randomization was carried out using the blind envelope method. Patients in the main group (n = 60) received iNO through nasal cannulas using the Tianox iNO therapy device (AIT-NO-Ol according to TU 32.50. 21-001-07623615-2017) in addition to the therapy according to the standard of care at the study center. Inhalations were carried out with high doses of NO, namely 200 ppm for 15 minutes 3 times a day, regardless of food intake. Patients in the control group (n = 60) received only the therapy recommended by the standard of care at the study center. Clinical and laboratory parameters were assessed and safety of the therapy was monitored during the study.Results. No significant differences were identified between the main group and the control group in demographic, clinical, laboratory and instrumental data at baseline. Patients receiving iNO as an adjunct to standard therapy had a more significant improvement in clinical symptoms starting from the 3rd day and better oxygenation parameters on the 7th day of therapy. There was a more significant decrease in the level of C-reactive protein on the 5th and 7th days of therapy and a more significant decrease in the level of leukocytes on the 5th day in the main group. The duration of hospitalization in the main group was significantly shorter than that in the control group. NO inhalation was not associated with any side effects and was well tolerated.Conclusion. The use of high doses of NO has a positive effect on the clinical status, markers of inflammation, reduces the length of hospitalization, and demonstrates good tolerability and safety in patients with CAP.
- Open Access
- 17 November 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 20,p. 128-137
Inhaled nitric oxide: well-known and new therapeutic indications
The use of nitric oxide is widespread in medical practice. Inhaled form of NO in patients with respiratory disease is especially interesting. As an inhalation therapy, nitric oxide reaches well-ventilated areas of the lungs, having a negligible systemic effect due to its rapid inactivation in the bloodstream. It has long been known that inhaled NO improves oxygenation in various pathological conditions. Low doses of inhaled nitric oxide are known as a vasodilator in patients with pulmonary hypertension, its use is possible even in newborns with hypoxemic respiratory failure and persistent pulmonary hypertension. In turn, high doses are used in the treatment of infectious lung diseases, besides, another surge of scientific interest in nitric oxide arose during the coronavirus pandemic. Although the antimicrobial potential of nitric oxide is widely known, it is little used in clinical practice. Endogenous antimicrobial activity is largely mediated by high local concentrations of NO. Numerous preclinical studies have demonstrated that NO has general static and bactericidal activity against viruses, bacteria, protozoa and fungi/yeast in vitro. Due to the dose-dependent positive and negative effects of NO, safety and efficacy tests of NO and its donors are needed to assess their role in the prevention and treatment of infections. This review provides information on the chemical structure, features of metabolism and delivery of inhaled NO, and also pays special attention to the antimicrobial effect in various diseases of the pulmonological profile.
- 17 November 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 20,p. 128-137
Open AccessInhaled nitric oxide: well-known and new therapeutic indications
The use of nitric oxide is widespread in medical practice. Inhaled form of NO in patients with respiratory disease is especially interesting. As an inhalation therapy, nitric oxide reaches well-ventilated areas of the lungs, having a negligible systemic effect due to its rapid inactivation in the bloodstream. It has long been known that inhaled NO improves oxygenation in various pathological conditions. Low doses of inhaled nitric oxide are known as a vasodilator in patients with pulmonary hypertension, its use is possible even in newborns with hypoxemic respiratory failure and persistent pulmonary hypertension. In turn, high doses are used in the treatment of infectious lung diseases, besides, another surge of scientific interest in nitric oxide arose during the coronavirus pandemic. Although the antimicrobial potential of nitric oxide is widely known, it is little used in clinical practice. Endogenous antimicrobial activity is largely mediated by high local concentrations of NO. Numerous preclinical studies have demonstrated that NO has general static and bactericidal activity against viruses, bacteria, protozoa and fungi/yeast in vitro. Due to the dose-dependent positive and negative effects of NO, safety and efficacy tests of NO and its donors are needed to assess their role in the prevention and treatment of infections. This review provides information on the chemical structure, features of metabolism and delivery of inhaled NO, and also pays special attention to the antimicrobial effect in various diseases of the pulmonological profile.